<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907606</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH-XW1401</org_study_id>
    <nct_id>NCT02907606</nct_id>
  </id_info>
  <brief_title>Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study</brief_title>
  <official_title>Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Valley Biotechnology Incorporated</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and
      dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and
      detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liquid biopsy, specifically through the assessment of circulating tumor DNA(ctDNA) from
      peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic
      monitoring.

      Urinary samples are completely non-invasive and easily obtainable compared to blood and
      tissue extraction. To date, only a limited number of published studies have examined the
      feasibility of ctDNA detection from urine.

      This study will collect tumor tissues, pretreatment peripheral blood samples and urine
      samples from different TNM stages of NSCLC patients, and detect EGFR gene mutations in paired
      samples.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>The concordant frequency of genomic results among tumor tissue DNA, urinary ctDNA and peripheral blood ctDNA.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference of urine ctDNA detection effectiveness between different TNM stages NSCLC patients.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of urine ctDNA concentration preoperative,intraoperative and 3 days after surgery with clinical features and prognosis.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lead time of tumor relapse detection by urine ctDNA than tumor markers and radiographic approaches.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary ctDNA predictive value for locoregional recurrence and distant metastasis.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Carcinoma</condition>
  <condition>Non-small-cell Lung Cancer</condition>
  <condition>Lung Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh tumor tissue, peripheral blood samples and urinary samples will be collected from each
      patient.

      Time:Preoperative, intraoperative, 3 days and 1、6、12 months after surgery.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically confirmed stage non-small cell lung cancer patients with paired tumor
        tissue, peripheral blood samples, and urinary samples.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 80 years

          -  Histologically confirmed diagnosis of stage non-small cell lung cancer undergoing
             surgical resection

          -  Completed and explicit information about TNM staging

          -  Paired specimens including tumor tissues, and both peripheral blood samples and
             urinary samples before and after surgery.

          -  Patients must have given written informed consent

        Exclusion Criteria:

          -  Unable to comply with the study procedure

          -  Malignant tumor history within the past 5 years

          -  Coexisting small cell lung cancer

          -  Unqualified tissue, blood or urine samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Li, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Li, M.D</last_name>
    <phone>86-10-88326652</phone>
    <email>dr.lixiao@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People'S Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>+86-010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao Li, M.D</last_name>
      <phone>+86-10-88326652</phone>
      <email>dr.lixiao@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hao Li, M.D</last_name>
      <phone>+86-10-88326650</phone>
      <phone_ext>Li</phone_ext>
      <email>lihao_pkuhsc@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao Li, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016 Oct;11(10):1690-700. doi: 10.1016/j.jtho.2016.05.035. Epub 2016 Jul 25.</citation>
    <PMID>27468937</PMID>
  </reference>
  <reference>
    <citation>Su YH, Wang M, Brenner DE, Norton PA, Block TM. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci. 2008 Aug;1137:197-206. doi: 10.1196/annals.1448.027.</citation>
    <PMID>18837947</PMID>
  </reference>
  <reference>
    <citation>Lin SY, Dhillon V, Jain S, Chang TT, Hu CT, Lin YJ, Chen SH, Chang KC, Song W, Yu L, Block TM, Su YH. A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J Mol Diagn. 2011 Sep;13(5):474-84. doi: 10.1016/j.jmoldx.2011.05.005. Epub 2011 Jul 2.</citation>
    <PMID>21726666</PMID>
  </reference>
  <reference>
    <citation>Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014 Jun 15;5(11):3607-10.</citation>
    <PMID>25003820</PMID>
  </reference>
  <reference>
    <citation>Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015 Jan;5(1):64-71. doi: 10.1158/2159-8290.CD-14-0742. Epub 2014 Oct 16.</citation>
    <PMID>25324352</PMID>
  </reference>
  <reference>
    <citation>Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9. Review.</citation>
    <PMID>23836314</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Jun Wang</investigator_full_name>
    <investigator_title>Chief of Thoracic Department</investigator_title>
  </responsible_party>
  <keyword>Non-small-cell Lung Cancer</keyword>
  <keyword>circulating tumor DNA</keyword>
  <keyword>urine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not make individual participant data (IPD) available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

